474 related articles for article (PubMed ID: 14752399)
1. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
2. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
4. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
5. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy.
Baudin E
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):228-39. PubMed ID: 17315031
[TBL] [Abstract][Full Text] [Related]
8. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
9. Advances in chemotherapy and biotherapy of endocrine tumors.
Oberg K
Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
12. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
13. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
14. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
Guillermet-Guibert J; Lahlou H; Pyronnet S; Bousquet C; Susini C
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):535-51. PubMed ID: 16183526
[TBL] [Abstract][Full Text] [Related]
15. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
16. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostics and treatment of neuroendocrine tumors of the digestive tract in the light of the present standards].
Szczeblowska D
Pol Merkur Lekarski; 2007 May; 22(131):437-41. PubMed ID: 17679390
[TBL] [Abstract][Full Text] [Related]
19. Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract.
Oberg K
Curr Opin Oncol; 1994 Jul; 6(4):441-51. PubMed ID: 7803546
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for gastro-enteropancreatic endocrine tumours.
O'Toole D; Hentic O; Corcos O; Ruszniewski P
Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
